Hegele Robert A
Robarts Research Institute, 406-100 Perth Drive, London, Ontario N6A 5K8, Canada.
Trends Cardiovasc Med. 2004 May;14(4):133-7. doi: 10.1016/j.tcm.2004.02.001.
The metabolic syndrome (MetS) is a common multiplex cluster of phenotypes strongly related to cardiovascular disease that includes central obesity with hypertension, dyslipidemia, and type 2 diabetes. The core molecular defect of the MetS is insulin resistance; indeed, the terms "MetS" and "insulin resistance syndrome" often are used interchangeably. The successful translation to clinical medicine of molecular genetic research on other rare monogenic metabolic disorders has stimulated the evaluation of such rare monogenic forms of insulin resistance as partial lipodystrophy resulting from mutations in either LMNA or PPARG genes. Careful phenotypic evaluation of carriers of monogenic insulin resistance using a range of diagnostic methods--an approach sometimes called "phenomics"--may help to find early presymptomatic biomarkers of cardiovascular disease, which, in turn, may uncover new pathways and targets for interventions for the common MetS, diabetes, and atherosclerosis.
代谢综合征(MetS)是一组与心血管疾病密切相关的常见复合表型,包括伴有高血压、血脂异常和2型糖尿病的中心性肥胖。代谢综合征的核心分子缺陷是胰岛素抵抗;事实上,“代谢综合征”和“胰岛素抵抗综合征”这两个术语经常互换使用。对其他罕见单基因代谢紊乱的分子遗传学研究成功转化为临床医学,这激发了人们对罕见单基因形式胰岛素抵抗的评估,比如由LMNA或PPARG基因突变导致的部分脂肪营养不良。使用一系列诊断方法对单基因胰岛素抵抗携带者进行仔细的表型评估——这种方法有时被称为“表型组学”——可能有助于找到心血管疾病的早期症状前生物标志物,进而可能揭示针对常见代谢综合征、糖尿病和动脉粥样硬化的新干预途径和靶点。